来源：环球时报 研发团队同时强调严格遵守国家医疗规范的重要性，正审慎探索AI与人类医务人员的高效协作模式， 并确保在技术完全成熟后再投入临床推广，目前正着力扩大AI医生精准诊疗的疾病覆盖面。这一里程 碑事件揭示了中国人工智能如何快速成长为医疗基础设施的关键组件，通过与人脑智慧互补应对现代医 学挑战。作为医疗AI创新浪潮的组成部分，该进展引发关于自动化与人类判断如何平衡的重要思考。 中国人工智能医院展现的优异成果为AI医疗未来融入患者体验并赢得信任提供了前瞻视野。（作者梅 莉莎·卢尼斯，刘长煌译） 该医院的AI医护人员通过大型语言模型驱动的智能体进行自主沟通。该系统模拟了覆盖患者护理每个 阶段的完整闭环流程：从院前程序、分诊和挂号，到咨询、检查、诊断、开处方、康复和随访。通过分 析海量医学文献并持续学习，这些AI医生可自主优化诊断和治疗技能。 这家AI医院短短几天内处理了超过1万名虚拟患者。研究人员说，假设人类医生平均每周治疗100名患 者，完成这一工作量通常需要约两年时间。AIR执行院长刘洋表示，这项研究是医疗领域的变革性突 破。这家AI医院将改变医生诊断和治疗患者的方式，为医疗专业人员和公众带来巨大益处。这 ...

Core Insights - Doximity, Inc. reported better-than-expected earnings for Q4, with earnings of 38 cents per share, surpassing the analyst consensus estimate of 27 cents per share [1] - The company achieved quarterly sales of $138.29 million, exceeding the analyst consensus estimate of $133.73 million [1] Financial Performance - Doximity closed fiscal 2025 with record engagement, strong profits, and 20% annual revenue growth [2] - The company guided for fiscal Q1 revenue of $139 million to $140 million, below estimates of $143.34 million [2] - Full-year 2026 revenue is forecasted to be between $619 million to $631 million, compared to estimates of $634.6 million [2] Stock Performance - Following the earnings announcement, Doximity shares fell by 9.8%, trading at $52.72 [3] - Analysts adjusted their price targets for Doximity after the earnings report [3] Analyst Ratings - Needham analyst Scott Berg maintained a Buy rating but lowered the price target from $82 to $67 [8] - Canaccord Genuity analyst Richard Close maintained a Hold rating and reduced the price target from $71 to $50 [8] - Raymond James analyst Brian Peterson maintained an Outperform rating, lowering the price target from $83 to $65 [8] - Truist Securities analyst Jailendra Singh maintained a Hold rating and slashed the price target from $58 to $52 [8]

Singapore, May 16, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL or the “Company”), today announced that it has begun exclusive negotiations for a US$1 billion BTC acquisition that will diversify its treasury reserves to a very large extent, while maintaining its core focus on medical services expansion. This is a major strategic financial initiative to strengthen its balance sheet and support its aggressive expansion across Asia’s high-growth healthcare markets. Strategic Financial Restruc ...

Core Viewpoint - SRx Health Solutions, Inc. is diversifying its treasury strategy by purchasing Ethereum (ETH) and has sold $1.5 million of Solana Tokens (SOL) to enhance long-term value for shareholders [1][2]. Company Overview - SRx Health Solutions, Inc. is a leading integrated healthcare services provider in Canada, operating across all ten provinces and focusing on specialty healthcare [3]. - The company combines industry knowledge, technology, and a patient-centric approach to deliver customized healthcare solutions [3].

Healthcare stocks have been under pressure in the U.S. due to increasing regulatory headwinds and rising costs.*Stock prices used were the afternoon prices of May 13, 2025. The video was published on May 15, 2025. ...

+91 226 842 1482 With Nifty nearing 25,000, we are now back to usual business after a dramatic weekend that culminated in India-Pakistan ceasefire (an uneasy calm, but we'll take it). We had advised in our previous notes to buy the dip given instances of sharp market recovery immediately once the escalation is behind. This report marks a return from the geopolitical Nikhil Arela to the fundamental, as we dissect the earnings to see what lies ahead. We retain our nikhil.arela@bernsteinsg.com positive view on ...

P3 Health Partners (PIII) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Speaker0 Good day, and welcome to the P3 Health Partners First Quarter twenty twenty five Earnings Conference Call. All participants will be in listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Brian Halstead. Please go ahead. Speaker1 Thank you, operator, and thank you for joining us today. Before we proceed with the call, I would like to remind everyone that certain statements ...

EPS Improved 90% Year-Over-Year to $(0.37) Adjusted EBITDA1 Loss Improved 54% Year-Over-Year to $(0.6) Million Adjusted EBITDA Margin1 Improved (9)%, a 865 Basis Point Expansion Year-Over-Year TAMPA, Fla., May 15, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions Inc. (NYSE American: SRXH) (the “Company” or "SRx", previously known as “Better Choice”), a leading global health and wellness company, today announced its results for the first quarter ended March 31, 2025. "We have executed a digital first strategy ...

Core Viewpoint - McKesson Corporation plans to spin off its Medical-Surgical Solutions segment into an independent company, referred to as NewCo, to enhance shareholder value and focus on strategic growth priorities in its remaining segments [1][2][4]. Deal Overview - The spin-off is part of McKesson's disciplined portfolio management strategy, which has previously included significant divestitures that unlocked shareholder value [2]. - The Medical-Surgical Solutions segment accounts for only 3.2% of McKesson's total revenue, with FY25 revenue around $11.4 billion, and has experienced sluggish growth since 2020 [4][17]. Financial Performance - For FY25, McKesson reported consolidated revenues of $359.1 billion, a 16.2% increase year-over-year from $309.0 billion in FY24 [12]. - In 4Q25, revenues reached $90.8 billion, up 18.9% year-over-year, driven by growth in the U.S. Pharmaceutical segment [10]. - Net income for FY25 was $3.3 billion, a 9.8% increase year-over-year, while adjusted net income was $4.2 billion, up 15.1% [12]. Strategic Focus Post-Spin-Off - After the spin-off, McKesson will concentrate on higher growth and higher margin opportunities in Oncology and Biopharma Solutions [3]. - The company has made recent acquisitions, including Rx Savings Solutions and plans to acquire a controlling stake in Core Ventures, to strengthen its core operations [3]. Long-Term Growth Targets - McKesson reaffirms its long-term adjusted earnings per diluted share growth target of 12% to 14% and updates the U.S. Pharmaceutical segment's long-term adjusted segment operating profit growth target to 6% to 8% [13][14].

I'm quite familiar with UnitedHealthcare "UNH" (NYSE: UNH ), as the healthcare giant towers over the skyline of my home state, Connecticut. I also have a confession to make. I recently purchased UNH's stock atAre You Getting The Returns You Want? Invest alongside the Financial Prophet's All-Weather Portfolio (2024 69% return) and achieve optimal results in any market.The Daily Prophet Report provides crucial information before the opening bell rings each morning.Implement my Covered Call Dividend Plan and e ...